MedTrace Logo

Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).

NCT02909088 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-10-26

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam in reducing stuttering symptoms.

It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the SSI-IV total score, the CGI, SSS and OASES.

Conditions

  • Stuttering, Adult
  • Childhood-onset Fluency Disorder
  • Speech Disorders
  • Language Disorders
  • Communication Disorder

Interventions

DRUG

Ecopipam 50mg

DRUG

Ecopipam 100mg

Sponsors & Collaborators

  • University of California Riverisde School of Medicine

    collaborator UNKNOWN

  • Gerald Maguire, MD

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-08-31
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02909088 on ClinicalTrials.gov